Literature DB >> 16563567

Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease.

Alireza Kashani1, Catalina Betancur, Bruno Giros, Etienne Hirsch, Salah El Mestikawy.   

Abstract

Glutamatergic pathways play a key role in the functional organization of neuronal circuits involved in Parkinson disease (PD). Recently, three vesicular glutamate transporters (VGLUT1-3) were identified. VGLUT1 and VGLUT2 are responsible for the uploading of glutamate into synaptic vesicles and are the first specific markers of glutamatergic neurons available. Here, we analyzed the expression of VGLUT1 and VGLUT2 in autopsy tissues of PD patients and matched controls using Western blot and immunoautoradiography. VGLUT1 and VGLUT2 expression was increased in the Parkinsonian putamen by 24% and 29%, respectively (p<0.01). In contrast, only VGLUT1 was dramatically decreased in the prefrontal and temporal cortex of PD patients (approximately 50%, p<0.01 and p<0.001, respectively). These findings demonstrate the existence of profound alterations of glutamatergic transmission in PD, which are likely to contribute to the motor and cognitive impairments associated with the disease, and should thus be taken into account in the treatment of PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563567      PMCID: PMC1976623          DOI: 10.1016/j.neurobiolaging.2006.02.010

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  56 in total

Review 1.  VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate.

Authors:  Robert T Fremeau; Susan Voglmaier; Rebecca P Seal; Robert H Edwards
Journal:  Trends Neurosci       Date:  2004-02       Impact factor: 13.837

2.  Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1.

Authors:  Nathan R Wilson; Jiansheng Kang; Emily V Hueske; Tony Leung; Helene Varoqui; Jonathan G Murnick; Jeffrey D Erickson; Guosong Liu
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

Review 3.  Dopamine/glutamate interactions in Parkinson's disease.

Authors:  K W Lange; J Kornhuber; P Riederer
Journal:  Neurosci Biobehav Rev       Date:  1997-07       Impact factor: 8.989

4.  Thalamic inputs to striatal interneurons in monkeys: synaptic organization and co-localization of calcium binding proteins.

Authors:  M Sidibé; Y Smith
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

5.  SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease.

Authors:  Y Imon; H Matsuda; M Ogawa; D Kogure; N Sunohara
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

6.  Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation.

Authors:  Xavier Drouot; Satoru Oshino; Bechir Jarraya; Laurent Besret; Haruhiko Kishima; Philippe Remy; Julien Dauguet; Jean Pascal Lefaucheur; Frédéric Dollé; Françoise Condé; Michel Bottlaender; Marc Peschanski; Yves Kéravel; Philippe Hantraye; Stéphane Palfi
Journal:  Neuron       Date:  2004-12-02       Impact factor: 17.173

7.  Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease.

Authors:  P Anglade; A Mouatt-Prigent; Y Agid; E Hirsch
Journal:  Neurodegeneration       Date:  1996-06

8.  An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size.

Authors:  S M Wojcik; J S Rhee; E Herzog; A Sigler; R Jahn; S Takamori; N Brose; C Rosenmund
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-21       Impact factor: 11.205

9.  Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites.

Authors:  Robert T Fremeau; Kaiwen Kam; Tayyaba Qureshi; Juliette Johnson; David R Copenhagen; Jon Storm-Mathisen; Farrukh A Chaudhry; Roger A Nicoll; Robert H Edwards
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

10.  Increased expression of the Drosophila vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease in quantal content.

Authors:  Richard W Daniels; Catherine A Collins; Maria V Gelfand; Jaime Dant; Elizabeth S Brooks; David E Krantz; Aaron DiAntonio
Journal:  J Neurosci       Date:  2004-11-17       Impact factor: 6.167

View more
  47 in total

1.  Satb1 ablation alters temporal expression of immediate early genes and reduces dendritic spine density during postnatal brain development.

Authors:  Michael A Balamotis; Nele Tamberg; Young Jae Woo; Jingchuan Li; Brian Davy; Terumi Kohwi-Shigematsu; Yoshinori Kohwi
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

2.  Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys.

Authors:  Rosa M Villalba; Yoland Smith
Journal:  J Comp Neurol       Date:  2011-04-01       Impact factor: 3.215

Review 3.  The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states.

Authors:  Yoland Smith; Dinesh Raju; Bijli Nanda; Jean-Francois Pare; Adriana Galvan; Thomas Wichmann
Journal:  Brain Res Bull       Date:  2008-09-19       Impact factor: 4.077

Review 4.  Genetic inactivation of the vesicular glutamate transporter 2 (VGLUT2) in the mouse: what have we learnt about functional glutamatergic neurotransmission?

Authors:  Asa Wallén-Mackenzie; Hanna Wootz; Hillevi Englund
Journal:  Ups J Med Sci       Date:  2010-02       Impact factor: 2.384

5.  PhIP exposure in rodents produces neuropathology potentially relevant to Alzheimer's disease.

Authors:  Tauqeerunnisa Syeda; Rachel M Foguth; Emily Llewellyn; Jason R Cannon
Journal:  Toxicology       Date:  2020-03-10       Impact factor: 4.221

6.  Reduced cortical innervation of the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Abraham Mathai; Yuxian Ma; Jean-Francois Paré; Rosa M Villalba; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2015-02-12       Impact factor: 13.501

7.  Striatal spine plasticity in Parkinson's disease: pathological or not?

Authors:  Y Smith; R M Villalba; D V Raju
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

Review 8.  Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.

Authors:  Paul T Francis
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

Review 9.  Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine?

Authors:  R M Villalba; Y Smith
Journal:  Neuroscience       Date:  2013-07-16       Impact factor: 3.590

10.  Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson's disease.

Authors:  Amélie C Lanoue; Gene J Blatt; Jean-Jacques Soghomonian
Journal:  Brain Res       Date:  2013-07-23       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.